You are here: Home » International » News » Companies
Business Standard

AstraZeneca's Covid-19 vaccine to begin clinical trials in China this year

AstraZeneca plans to start early and mid-stage clinical trials of its Covid-19 vaccine candidate in China this year, a senior executive said, as it prepares a global rollout of the vaccine

Coronavirus Vaccine | AstraZeneca | Coronavirus Tests

Reuters  |  SHANGHAI 

Photo: Bloomberg
Representative photo of a vaccine

SHANGHAI (Reuters) - Plc plans to start early and mid-stage clinical trials of its COVID-19 vaccine candidate in this year, a senior executive said on Friday, as it prepares a global rollout of the vaccine.

The vaccine candidate is already in the final stage of clinical trials in other countries, and and its partner on the project, the University of Oxford, expect data from the late-stage trials this year.

If successful, they will file for emergency approvals in as many countries as possible at the same time, its CEO, Pascal Soriot, said this week.

In China, the company has a deal with Shenzhen Kangtai Biological Products to manufacture the vaccine in the country.

Under the agreement, Shenzhen Kangtai, one of China's top vaccine makers, will ensure it has annual production capacity of at least 100 million doses of the experimental shot AZD1222 by the end of this year.

The vaccine may be approved for use in by mid-2021 after gathering safety data from Phase 1 and Phase 2 trials in and efficacy data from Phase 3 trials overseas, Leon Wang, head of AstraZeneca's China operation told Reuters.

Wang said its trials in China would use vaccines manufactured by local partner Shenzhen Kangtai.


(Reporting by Roxanne Liu and Brenda Goh. Editing by Gerry Doyle)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, November 06 2020. 09:46 IST